Figure 2 from Β-Catenin Drives Butyrophilin-like Molecule Loss and Γδ T-cell Exclusion in Colon Cancer

γδ T cells are excluded from mouse and human gut tumors. A, Images of SI tissue from 4 WT (Cre-negative), tumor-bearing Villin-CreERT2;ApcF/+ (VA) and tumor-bearing Villin-CreERT2;ApcF/+;KrasG12D (VAK) mice stained for Trdc mRNA; scale bar, 500 μm. B, γδ T-cell numbers in SI tissue of indicated models. Each dot represents one mouse (n = 11 WT, 3 VA, 3 VAK). C, Representative flow cytometry plot of CD8α and γδTCR expressions on total CD3+ cells in the small intestine of WT mice. CD8α+ γδ T-cell frequency in SI of indicated models. Each dot represents one mouse (n = 9 WT, 4 VA, 5 VAK). D, Images of SI from indicated models (n = 4/group) stained for Trdc mRNA; scale bar, 500 μm. E, γδ T-cell numbers in SI of indicated models. Each dot represents one mouse (n = 3 WT, 4 VAF/F, 4 VAF/FK). F, Image of γδ T-cell staining in tumor adjacent tissue and tumor tissue from human colon cancer sections (Scotland cohort, n = 141) where arrows indicate positively stained cells; scale bar, 500 μm. G, Density of γδ T cells in human colon cancer sections in three different patient cohorts: Scotland (n = 141), Norway (n = 71), and Thailand (n = 122). γδ T cells identified by IHC in full sections were quantified in tumor adjacent tissue or tumor tissue using Visiopharm. Data are presented as median ± min/max. H, Expressions of TRGV4 and TRGV9 mRNA in human colon cancer samples (n = 82) from the Scotland cohort determined by TempO-Seq. Data are presented as mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (paired t test or one-way ANOVA followed by Dunnett post hoc test).